Literature DB >> 8807334

A sensitive mutation screening strategy for Fabry disease: detection of nine mutations in the alpha-galactosidase A gene.

L C Blanch1, C Meaney, C P Morris.   

Abstract

Fabry disease is an X-linked recessive lysosomal storage disorder caused by a deficiency of alpha-galactosidase A (alpha-gal; EC 3.2.1.22). In the past, it has been difficult to give an unequivocal diagnosis of carrier status in Fabry disease because of the overlap between normal and heterozygote enzyme levels. To facilitate rapid and accurate carrier and hemizygote detection, a mutation detection strategy was devised to determine the lesion in our Fabry disease patients. The seven alpha-gal exons and adjacent intron boundaries from a representative member of each kindred were PCR amplified and analysed for the presence of sequence alterations by single-stranded conformation polymorphism (SSCP) analysis followed by PCR sequencing. Here we report the use of this strategy in the detection and analysis of the causative mutations in 9 patients with classic severe Fabry disease. Three deletions of 1-, 2-, and 3-bp (987delC, 717delAA, and delta E358), five amino acid substitutions (C52R, G128E, P205T, M284T, and N298K) and a mutation that affects the initiating methionine (M1I) were found in these patients. Counting a previously reported mutation, this strategy has now successfully detected all the Fabry disease mutations present in the 10 kindreds that have been analysed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807334     DOI: 10.1002/(SICI)1098-1004(1996)8:1<38::AID-HUMU5>3.0.CO;2-L

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  17 in total

Review 1.  Progressive renal failure despite long-term biweekly enzyme replacement therapy in a patient with Fabry disease secondary to a new α-galactosidase mutation of Leu311Arg (L311R).

Authors:  Keisuke Suzuki; Naoto Miura; Wataru Kitagawa; Shinkichi Suzuki; Atsushi Komatsuda; Kazuhiro Nishikawa; Daisuke Watanabe; Hirokazu Imai
Journal:  Clin Exp Nephrol       Date:  2011-07-15       Impact factor: 2.801

2.  Target-enrichment sequencing and copy number evaluation in inherited polyneuropathy.

Authors:  Wei Wang; Chen Wang; D Brian Dawson; Erik C Thorland; Patrick A Lundquist; Bruce W Eckloff; Yanhong Wu; Saurabh Baheti; Jared M Evans; Steven S Scherer; Peter J Dyck; Christopher J Klein
Journal:  Neurology       Date:  2016-04-13       Impact factor: 9.910

3.  Retinal sphingolipids and their very-long-chain fatty acid-containing species.

Authors:  Richard S Brush; Julie-Thu A Tran; Kimberly R Henry; Mark E McClellan; Michael H Elliott; Md Nawajes A Mandal
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-14       Impact factor: 4.799

4.  The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies.

Authors:  Susana Ferreira; Alberto Ortiz; Dominique P Germain; Miguel Viana-Baptista; António Caldeira-Gomes; Marta Camprecios; Maria Fenollar-Cortés; Ángel Gallegos-Villalobos; Diego Garcia; José Antonio García-Robles; Jesús Egido; Eduardo Gutiérrez-Rivas; José Antonio Herrero; Sebastián Mas; Raluca Oancea; Paloma Péres; Luis Manuel Salazar-Martín; Jesús Solera-Garcia; Helena Alves; Scott C Garman; João Paulo Oliveira
Journal:  Mol Genet Metab       Date:  2014-11-09       Impact factor: 4.797

5.  Structure-function relationships in alpha-galactosidase A.

Authors:  Scott C Garman
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

6.  Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.

Authors:  Ozlem Goker-Alpan; Michael J Gambello; Gustavo H B Maegawa; Khan J Nedd; Daniel J Gruskin; Larry Blankstein; Neal J Weinreb
Journal:  JIMD Rep       Date:  2015-08-25

Review 7.  Fabry's disease: an example of cardiorenal syndrome type 5.

Authors:  Aashish Sharma; Marco Sartori; Jose J Zaragoza; Gianluca Villa; Renhua Lu; Elena Faggiana; Alessandra Brocca; Luca Di Lullo; Sandro Feriozzi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

8.  Structural characterization of mutant alpha-galactosidases causing Fabry disease.

Authors:  Kanako Sugawara; Kazuki Ohno; Seiji Saito; Hitoshi Sakuraba
Journal:  J Hum Genet       Date:  2008-07-17       Impact factor: 3.172

Review 9.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

10.  Short-term efficacy of enzyme replacement therapy in Korean patients with Fabry disease.

Authors:  Jin-Ho Choi; Young Mi Cho; Kwang-Sun Suh; Hye-Ran Yoon; Gu-Hwan Kim; Sung-Su Kim; Jung Min Ko; Joo Hoon Lee; Young Seo Park; Han-Wook Yoo
Journal:  J Korean Med Sci       Date:  2008-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.